title: Dehydroabietic acid, a diterpene, improves diabetes and hyperlipidemia in obese diabetic KK-Ay mice.
abstract: Terpenoids, which are contained in a large number of dietary and herbal plants, have many biological effects. In this study, the effects of dehydroabietic acid (DAA), a diterpene, on glucose and lipid metabolism were examined using obese diabetic KK-Ay mice. We showed here that DAA treatment decreased not only plasma glucose and insulin levels but also plasma triglyceride (TG) and hepatic TG levels. To examine the mechanism underlying the effects of DAA, the production of inflammatory cytokines was measured. It was shown that the DAA treatment suppressed the production of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNFalpha) (proinflammatory cytokines) and increased that of adiponectin (an anti-inflammatory cytokine). As a result of the changes in the production of inflammatory cytokines caused by the DAA treatment, the accumulation of macrophages in adipose tissues was reduced. These results indicate that treatment with DAA improves the levels of plasma glucose, plasma insulin, plasma TG, and hepatic TG through the decrease in the macrophage infiltration into adipose tissues, suggesting that DAA is a useful food-derived compound for treating obesity-related diseases.
authors.affiliation: Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto, Japan.
authors.forename: Min-Sook
authors.initials: MS
authors.lastname: Kang
authors.forename: Shizuka
authors.initials: S
authors.lastname: Hirai
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Goto
authors.forename: Kayo
authors.initials: K
authors.lastname: Kuroyanagi
authors.forename: Young-Il
authors.initials: YI
authors.lastname: Kim
authors.forename: Kana
authors.initials: K
authors.lastname: Ohyama
authors.forename: Taku
authors.initials: T
authors.lastname: Uemura
authors.forename: Joo-Young
authors.initials: JY
authors.lastname: Lee
authors.forename: Tomoya
authors.initials: T
authors.lastname: Sakamoto
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Ezaki
authors.forename: Rina
authors.initials: R
authors.lastname: Yu
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Takahashi
authors.forename: Teruo
authors.initials: T
authors.lastname: Kawada
mesh_terms: D045784:Abietanes / Q000627:therapeutic use*; D052242:Adiponectin / Q000096:biosynthesis; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D018932:Chemokine CCL2 / Q000096:biosynthesis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008264:Macrophages / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008820:Mice, Obese; D009765:Obesity / Q000150:complications; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D045784:Abietanes; D052242:Adiponectin; C499919:Adipoq protein, mouse; D001786:Blood Glucose; C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D007328:Insulin; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; C013913:dehydroabietic acid